Replies to post #246977 on Biotech Values

[Mufaso]

VKTX- William Blair comments:

says that after Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom, investor enthusiasm in the NASH space has been invigorated.

VK2809 offers differentiation by specifically targeting the liver, which could translate to a clinical advantage for VK2809 compared to resmetirom, particularly in providing a more tolerable regimen with an improved safety profile.

BTIG has raised the price target from $31 to $36, with a Buy rating, based on this impressive data exceeding expectations and de-risking further clinical development. 
The analyst has increased modeled PoS for VK-2809 from 65% to 75%.